Clinical trial

Comparison of SARS-CoV-2, AdenoVIRus and Rhinovirus Infection of the Respiratory Epithelium in CHILdren vs. the eLDerly

Name
CHUBX 2021/43
Description
The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology that account for differences in the response and susceptibility to respiratory viruses. Epidemiology and cell-based data show that respiratory virus infections differentially affect children, adults or the elderly populations. The current worldwide pandemic of SARS-CoV-2 clearly highlighted this notion with a large part of the deaths occurring in the elderly population and very few deaths amongst children. This may be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. Less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium (BE) such as rhinovirus (RV) and adenovirus (AdV) cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determine virus susceptibility and virus propagation.
Trial arms
Trial start
2022-10-28
Estimated PCD
2025-04-28
Trial end
2025-04-28
Status
Recruiting
Treatment
SARS-CoV-2
Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.
Arms:
adults, children, elderly
Adenovirus (AdV)
Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors
Arms:
adults, children, elderly
Rhinovirus
RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study
Arms:
adults, children, elderly
No Intervention
no infection
Arms:
adults, children, elderly
Size
200
Primary endpoint
number of viral particles - Rhinovirus - Children -24
after 24 hours of infection
number of viral particles - Adenovirus - Children -24
after 24 hours of infection
number of viral particles - SARS-CoV-2 - Children-24
after 24 hours of infection
number of viral particles - Rhinovirus - Adults-24
after 24 hours of infection
number of viral particles - Adenovirus - Adults-24
after 24 hours of infection
number of viral particles - SARS-CoV-2 - Adults-24
after 24 hours of infection
number of viral particles - Rhinovirus - elderly-24
after 24 hours of infection
number of viral particles - Adenovirus - Elderly-24
after 24 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-24
after 24 hours of infection
Eligibility criteria
Inclusion Criteria: For pediatric patients requiring research-specific bronchial brushing: * Child under 18 years old, * Requiring bronchoscopy as part of routine care * Having informed and signed consent from the holders of parental authority For pediatric patients whose bronchial brushing will be carried out as part of their care and for those whose surgical waste will be collected for research: * Child under 18 years old, * Requiring as part of routine care bronchoscopy and brushing or bronchial fibroscopy under general anesthesia or surgical resection/lobectomy * Having expressed their non-opposition to their child's participation in research For adult patients: * Man or woman * Aged 18 or over * Requiring as part of the care, thoracic surgery such as lobectomy, pneumonectomy or lung transplantation in the Thoracic Surgery Department of Haut Lévêque du Chu Hospital in Bordeaux or inclusion in the TUBE study, described below. * having received an information note and not having objected to their participation in the research Exclusion Criteria: * No affiliation or non-beneficiary of a social security system * During a period of relative exclusion compared to another protocol * Patient born before 36 weeks of amenorrhea * Patient with a documented history of pulmonary fibrosis, primary pulmonary hypertension, cystic fibrosis, pulmonary malformation or chronic viral infections (hepatitis, HIV). * Patient with any dental, nasopharyngeal or bronchial infection with fever (\> 38°C) requiring systemic antibiotics in the previous 4 weeks
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}}
Updated at
2024-01-25

1 organization

4 products

1 indication

Product
SARS-CoV-2
Indication
COVID-19
Product
Adenovirus
Product
Rhinovirus